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GAMETE BIOLOGY
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Abstract
Purpose The aim of this study was to determine whether
BRCA1/2 mutation carriers produce fewer mature oocytes af-
ter ovarian stimulation for in vitro fertilization (IVF) with
preimplantation genetic diagnosis (PGD), in comparison to a
PGD control group.
Methods A retrospective, international, multicenter cohort
study was performed on data of first PGD cycles performed
between January 2006 and September 2015. Data were ex-
tracted from medical files. The study was performed in one
PGD center and three affiliated IVF centers in the Netherlands
and one PGD center in Belgium. Exposed couples underwent
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PGD because of a pathogenic BRCA1/2mutation, controls for
other monogenic conditions. Only couples treated in a long
gonadotropin-releasing hormone (GnRH) agonist-suppressive
protocol, stimulated with at least 150 IU follicle stimulating
hormone (FSH), were included. Women suspected to have a
diminished ovarian reserve status due to chemotherapy, auto-
immune disorders, or genetic conditions (other than BRCA1/2
mutations) were excluded. A total of 106 BRCA1/2 mutation
carriers underwent PGD in this period, of which 43 (20
BRCA1 and 23 BRCA2 mutation carriers) met the inclusion
criteria. They were compared to 174 controls selected by fre-
quency matching.
Results Thirty-eight BRCA1/2 mutation carriers (18 BRCA1
and 20 BRCA2 mutation carriers) and 154 controls proceeded
to oocyte pickup. The median number of mature oocytes was
7.0 (interquartile range (IQR) 4.0–9.0) in the BRCA group as
a whole, 6.5 (IQR 4.0–8.0) in BRCA1 mutation carriers, 7.5
(IQR 5.5–9.0) in BRCA2mutation carriers, and 8.0 (IQR 6.0–
11.0) in controls. Multiple linear regression analysis with
the number of mature oocytes as a dependent variable
and adjustment for treatment center, female age, female
body mass index (BMI), type of gonadotropin used, and
the total dose of gonadotropins administered revealed a
significantly lower yield of mature oocytes in the BRCA
group as compared to controls (p = 0.04). This finding
could be fully accounted for by the BRCA1 subgroup
(BRCA1 mutation carriers versus controls p = 0.02,
BRCA2 mutation carriers versus controls p = 0.50).
Conclusions Ovarian response to stimulation, expressed as
the number of mature oocytes, was reduced in BRCA1 but
not in BRCA2 mutation carriers. Although oocyte yield
was in correspondence to a normal response in all sub-
groups, this finding points to a possible negative influence
of the BRCA1 gene on ovarian reserve.
Keywords BRCA1/2mutations . Ovarian reserve .Mature
oocytes . IVF . Preimplantation genetic diagnosis
Introduction
Contradicting results have been published on a potential in-
fluence of mutations in the BRCA1 and BRCA2 genes on
ovarian reserve. Mutations in the BRCA genes are primarily
known for their predisposition to breast and ovarian cancer
[1]. The BRCA genes act as tumor suppressor genes and are
involved in DNA double-strand break repair [2]. An impaired
function leads to an accumulation of intracellular DNA dam-
age. This may affect cellular growth mechanisms, leading to
carcinogenic transformation [3]. Alternatively, accumulating
DNA damage may induce growth arrest, leading to apoptosis
[4]. Hypothetically, this may be illustrated in non-dividing cell
populations, e.g., the ovarian follicle pool.
Oktay et al. [5] were the first to observe a reduced ovarian
response to ovarian stimulation for in vitro fertilization (IVF)
in BRCA1mutation-positive cancer patients undergoing fertil-
ity preservation. This was not confirmed by another report on
the ovarian response to IVF stimulation in a combined group
of BRCA1/2 mutation carriers undergoing fertility preserva-
tion because of breast cancer and asymptomatic BRCA1/2
mutation carriers undergoing IVF with preimplantation genet-
ic diagnosis (PGD) [6]. Contradicting results have also been
published when assessing ovarian reserve in BRCA1/2 muta-
tion carriers using other endpoints. Several studies on age of
natural menopause reported an earlier menopause in both
BRCA1 and BRCA2 mutation carriers [7–9]. The majority of
studies using anti-Müllerian hormone (AMH) as an indicator
for the number of (pre-)antral follicles in the ovaries detected
lower levels of AMH in BRCA1 mutation carriers, not in
BRCA2 mutation carriers [10–13]. Studies using several other
reproductive outcome parameters (e.g., parity) did not point to a
reduced fecundity in BRCA1/2 mutation carriers [14–18].
Ovarian response to stimulation for IVF is a strong indica-
tor for ovarian reserve status [19]. Sufficient ovarian response
is particularly important in PGD, where transfer criteria pri-
marily involve genetic results. After a second selection on
embryo quality, only a minority of the obtained embryos will
be available for transfer. If a mutation in the BRCA1 and/or
BRCA2 gene is associated with a lower ovarian reserve, this
may have a negative effect on success chances of mutation
carriers undergoing IVF for infertility reasons, for fertility
preservation, as well as for PGD. PGD for BRCA1/2 muta-
tions has been performed for a decade now and the number of
couples treated each year has been growing steadily [20, 21].
The objective of the current study is to clarify whether
BRCA1/2 mutation carriers produce less mature oocytes after
ovarian stimulation for IVF/PGD.
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Material and methods
A retrospective, observational cohort study was carried out in
five centers: Maastricht University Medical Center (center 1)
and affiliated IVF centers University Medical Center Utrecht
(center 2), University Medical Center Groningen (center 3),
and Academic Medical Center Amsterdam (center 4), united
in the Dutch consortium for PGD, and Universitair Ziekenhuis
Brussel, Brussels, Belgium (center 5). The study period lasted
from the introduction of PGD for hereditary cancer syndromes
(i.e., 2006 for Brussels and 2008 for The Netherlands) until
September 2015.
The exposed group consisted of couples who underwent
IVF/PGD because of a pathogenic mutation in the BRCA1 or
BRCA2 gene in the female (the BBRCA group^). All muta-
tions were proven pathogenic by means that they had a veri-
fied significant disturbing effect on protein translation. The
control group consisted of couples who underwent PGD be-
cause of an autosomal dominant or recessive disorder not
known to be associated with a reduced ovarian reserve. For
the selection of controls, frequency matching was used: con-
trol couples were selected blinded for outcome, based on treat-
ment center and treatment period in order to obtain an equal
distribution in both groups [22]. For this purpose, a chrono-
logical overview of PGD treatments performed per PGD cen-
ter for autosomal dominant and recessive disorders (excluding
conditions known for a (potential) effect on ovarian reserve
(e.g., fragile X syndrome, myotonic dystrophy type 1) and
male BRCA1/2 mutation carriership) was created. Matching
was done per PGD center: PGD treatments for female BRCA1/
2mutations were identified, and (if available) four PGD treat-
ments for autosomal dominant or recessive disorders chrono-
logically performed closely before or after the PGD treatment
for BRCA1/2 were included as controls. In order to rule out
bias from repetitive cycles, only first treatment cycles were
included. First cycles with and without oocyte pick-up were
included in order to assess the cancelation rate because of poor
ovarian response in both groups.
Only treatments in a long gonadotropin-releasing hormone
(GnRH) agonist-suppressive protocol, with stimulation with
at least 150 IU follicle stimulating hormone (FSH) or human
menopausal gonadotropin (hMG) per day, were included in
order to obtain a homogenous study population with optimal
ovarian stimulation [23]. Other inclusion criteria for both
groups were: female age < 43 years, female body mass index
(BMI) < 35 kg/m2, and female endogenous FSH < 15 IU/l.
Exclusion criteria were a history of invasive (breast) cancer
up to 2 years prior to IVF/PGD treatment, ovarian surgery,
chemotherapy, pelvic radiation, polycystic ovary syndrome
that conforms the Rotterdam criteria [24], and known endo-
crine, autoimmune, or genetic abnormalities (potentially) as-
sociated with a reduced ovarian reserve (e.g., fragile X
premutation carriers, myotonic dystrophy type 1).
Final oocyte maturation was induced when sufficient dom-
inant follicles were seen at ultrasound (i.e., at least four folli-
cles > 14 mm in the Netherlands and at least three follicles >
17 mm in Brussels). The number of mature oocytes was
assessed at the moment of intracytoplasmic sperm injection
(ICSI). ICSI was used for fertilization in order to avoid con-
tamination of the zona pellicuda with residual spermatozoa.
Embryo biopsy was performed on day 3 after fertilization.
Single-cell analysis of the removed blastomeres was per-
formed using multiplex polymerase chain reaction (PCR), as
described elsewhere [20, 25, 26]. Data were extracted from
medical files.
Ethical approval
The study was approved by the Institutional Review Boards of
Maastricht University Medical Center (METC 14-4-163) and
Universitair Ziekenhuis Brussel (2014/383). All couples gave
their written informed consent for IVF/PGD treatment, and
the usage of their PGD data for scientific research before the
treatment was started.
Statistical analysis
Patient characteristics and outcome data are presented asmean
and standard deviation, median and interquartile range (IQR),
or frequency and percentage, depending on the distribution of
the variable. Where outcome data were not normally distrib-
uted, bivariate analyses were performed using non-parametric
tests (Mann-Whitney U test). A linear regression model was
used to assess an association between BRCA1/2 mutation sta-
tus and ovarian response in terms of the number of obtained
mature oocytes. The number of mature oocytes was trans-
formed using the square root, in order to obtain an approxi-
mately normal distribution of the residuals. Adjustments were
made for potential confounding factors, i.e., treatment center,
female age, female BMI, type of gonadotropin administered
(FSH or hMG), and total dose of gonadotropin administered.
These factors were incorporated because of a potential nega-
tive influence of an advanced age, higher BMI, and the use of
hMG on the number of mature oocytes yielded and because an
effect of the treatment center and the cumulative dose of go-
nadotropins applied could not be ruled out. Age and BMI
were both assessed as continuous and categorical variables
(age ≤ 30 versus > 30 years, age ≤ 35 versus > 35 years,
BMI ≤ 25 versus BMI > 25). Subgroup analyses were con-
ducted to determine potential differences in the primary out-
come between BRCA1mutation carriers and the control group
and BRCA2 mutation carriers and the control group. A sensi-
tivity analysis was performed excluding center 5, since this
center used the long agonist protocol particularly for expected
poor responders. Statistical analyses were performed using
SAS statistical analysis software for Windows, version 9.3.
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The study was powered on a previously reported difference
in obtained oocytes following IVF in BRCA carriers (7.9 (95%
CI 4.6–13.8) oocytes in BRCA mutation carriers compared to
11.3 (95% CI 9.1–14.1) oocytes in women without a BRCA
mutation [5]). The inclusion of 50 BRCA mutation carriers
and 200 controls would be sufficient to detect a difference
of the aforementioned magnitude, with alpha set at 0.05
and beta at 0.8.
Results
Patient characteristics
In total, 106 female BRCA1/2 mutation carriers underwent
PGD in the study period, of whom 66 (62.3%) had a BRCA1
mutation and 40 (37.7%) a BRCA2 mutation. Twelve carriers
had a history of invasive breast cancer and chemotherapy
(nine BRCA1 and three BRCA2 mutation carriers), and 51
carriers were excluded for other reasons (Table 1). Of the 43
included carriers, 20 (46.5%) had a BRCA1 mutation and 23
(53.5%) a BRCA2mutation. Of the 174 controls, 119 (68.4%)
underwent PGD because of an autosomal dominant condition
and 55 (31.6%) because of an autosomal recessive condition
(Table 2). An overview of the distribution of the couples over
the five centers is provided in supplemental Table 1.
Bivariate analyses
Thirty-eight out of 43 BRCA cycles and 154 out of 174 con-
trol cycles proceeded to oocyte pick-up. The cancelation rate
due to a poor response was 3/43 (7.0%) in the BRCA group
and 16/174 (9.3%) in the control group (p = 0.35). Themedian
number of cumulus oocyte complexes was 9.0 (IQR 5.8–11.0)
and 10.0 (IQR 7.0–14.0) in the BRCA and control group,
respectively (p = 0.05, Table 3). The median number of ma-
ture oocytes was 7.0 (IQR 4.0–9.0) and 8.0 (IQR 6.0–11.0,
p = 0.02), respectively. The observed difference in mature
oocytes could be fully accounted to women with a BRCA1
mutation: BRCA1 mutation carriers (n = 18) produced a me-
dian of 6.5 (IQR 4.0–8.0) mature oocytes, compared to 8.0
(IQR 6.0–11.0) in the control group (p = 0.01). This difference
was not observed in the BRCA2 subgroup (n = 20, median 7.5
(IQR 5.5–9.0) in the BRCA2 subgroup, p = 0.20).
There was no difference in the cumulative dose of exoge-
nous FSH administered between groups (1987.5 IU (IQR
1762.5–2812.5 IU) in the BRCA group as a whole,
1950.0 IU (IQR 1650.0–2550.0 IU) in the BRCA1 subgroup,
2137.5 IU (IQR 1800.0–3356.3 IU) in the BRCA2 subgroup,
and 1950.0 IU (IQR 1650.0–2575.0 IU)) in controls (all
p > 0.05, Table 3). As the number of mature oocytes was lower
in the BRCA group, we explored whether the ratio of adminis-
tered FSH per obtained mature oocyte obtained was higher in
this group (i.e., whether BRCA mutation carriers needed more
FSH to obtain the same amount of oocytes and/or produced less
oocytes when the same dose of FSHwas applied). In the BRCA
group as a whole, more FSH was administered per obtained
mature oocyte when compared to the control group (median
FSH/mature oocyte ratios 353.0 (IQR 210.7–521.9) and 250.0
(IQR 168.6–375.0), respectively, p = 0.03). The FSH/mature
oocyte ratio was highest in the BRCA1 subgroup (median
FSH/mature oocyte ratio 383.0 (IQR 208.3–521.9) in the
Table 1 The number of eligible






Reason for exclusion (n)
Breast cancer + chemotherapy 12a
Endocrine/autoimmune disorder 5b
Polycystic ovarian syndrome 3
Ovarian surgery 1
Other genetic conditions 1c
Regular IVF prior to PGD 0
Different IVF protocolsd 36
Only cycles with <150 IU FSH per day 5
First cycles included (n) 43 174
Cancel in the first cycle (n, %) 5/43 (11.6) 20/174 (11.5)
First cycles with oocyte pickup (n, %) 38/43 (88.4) 154/174 (88.5)
IVF in vitro fertilization, PGD preimplantation genetic diagnosis, FSH follicle stimulating hormone
a Five of these women were also treated in an IVF protocol other than a long GnRH agonist-suppressive protocol
b Two of these women were also treated in an IVF protocol other than a long GnRH agonist-suppressive protocol
c Female CHEK2 mutation
d Treatment in an IVF protocol other than a long GnRH agonist-suppressive protocol
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BRCA1 subgroup and 326.3 (IQR 203.6–600.0) in the
BRCA2 subgroup). The fraction of normally fertilized oo-
cytes (2PN oocytes) was comparable between groups
(Table 3). The pregnancy rate was lower in women with
a BRCA1 mutation, but this did not reach significance.
Multivariable analyses
Linear regression analyses with the square root transformed
number of mature oocytes as the dependent variable showed
that the difference in the number of mature oocytes between
the BRCA group and control group remained statistically sig-
nificant after adjustment for treatment center, female age, fe-
male BMI, type of gonadotropin (FSH or hMG), and cumu-
lative dose of FSH administered (p = 0.04, Table 4). Again,
this difference was only present in BRCA1mutation carriers as
compared to controls (p = 0.02), not in BRCA2 mutation car-
riers (p = 0.50).
Additional analyses were performed to allow for a possible
non-linear effect of female age and female BMI on the number
of mature oocytes, by introducing these variables as a dichot-
omous (instead of linear) variable in the multivariable model
(age ≤ 30 versus > 30 years, age ≤ 35 versus > 35 years, and
BMI ≤ 25 versus BMI > 25). This did not change the outcome.
A sensitivity analysis excluding center 5 (as stated above, the
fact that in this center the long agonist protocol was primarily
used for expected poor responders could have introduced bias)
did neither change the outcome.
Discussion
In this study, a lower number of mature oocytes was found in
women with a BRCA1 mutation in response to ovarian stim-
ulation for IVF/PGD.
Diverse studies have been reported on a possible dimin-
ished ovarian reserve in BRCAmutation carriers, using differ-
ent primary outcomes and study designs. Oktay et al. [5] were
the first to report a lower yield of oocytes in eight BRCA1, but
not in four BRCA2-mutated breast cancer patients. A case-
control study by Shapira et al. [6] found no difference in oo-
cyte yield according to BRCA mutation status in 62 BRCA
mutation-positive women. However, the inclusion of cancer
patients and patients stimulated in different IVF protocols and
the lack of clarity regarding minimal stimulation doses applied
may have obscured an existing difference.
Previous studies on ovarian reserve in BRCA1/2 mutation
carriers using non-IVF-related parameters did not show con-
sistent results. It is challenging, however, to study ovarian
reserve in BRCA1/2mutation carriers because of the presence





Female age (mean, SD) 31.4 ± 3.7 32.1 ± 4.1
Female BMI (mean, SD) 23.8 ± 3.0 23.9 ± 3.5
AD disorders (n, %) 43 (100.0) 119 (68.4)
Female carriers 42 59a
Male carriers n/a 57
Both partners 1 3
BRCA1 (n, %) 20 (46.5) n/a
BRCA2 (n, %) 22 (51.2) n/a
BRCA2 female + retinoblastoma male (n, %) 1 (2.3) n/a
Huntington’s disease n/a 25b
Neurofibromatosis type 1 n/a 12c
Myotonic dystrophy type 1d n/a 10
Familial adenomatous polyposis n/a 10
Spinocerebellar ataxia type 3 n/a 8
Marfan syndrome n/a 7
Other n/a 47e
AR disorders (n, %) n/a 55 (31.6)
Cystic fibrosis n/a 16
Spinal muscular atrophy n/a 13e
Other n/a 26
SD standard deviation, BMI body mass index, AD autosomal dominant, AR autosomal recessive, n/a not applicable
a One woman had both Peutz-Jeghers syndrome and porencephalia
b Of which five couples opted for exclusion PGD
cOf which two couples had two indications for PGD
dOnly males with myotonic dystrophy type 1 were included, since myotonic dystrophy type 1 is potentially
associated with a reduced ovarian reserve
e Of which one couple had two indications for PGD
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of several confounding factors in this particular population.
Firstly, breast cancer [27, 28] as well as its potential
gonadotoxic treatment [29] has a negative effect on ovarian
reserve. Secondly, many BRCA1/2 mutation carriers opt for a
risk-reducing salpingo-oophorectomy. The timing of this
event may be influenced by personal cancer history and relat-
ed to the menopausal transition. As a consequence, studies on
age at natural menopause in BRCA1/2 mutation carriers have
important limitations, as set out by van Tilborg et al. [30].
Two studies reported a younger age of natural menopause in
both BRCA1 and BRCA2 mutation carriers [8, 9]. A third
study found a younger age of menopause in BRCA1mutation
carriers with and without breast cancer [7]. Two other studies
did not detect a difference in the age of natural menopause
between carriers and non-carriers [30, 31]. Studies were trou-
bled by both the inclusion [7] and exclusion of breast cancer
patients [8], the exclusion of women who experienced men-
opause due to other reasons than natural menopause [8], bias
resulting from informative censoring due to risk-reducing
salpingo-oophorectomy uptake [9], the inclusion of only
few women who had actually reach natural menopause [31],
and/or other forms of bias [30]. Three studies have found a
lower AMH in BRCA1 mutation carriers and not in BRCA2
mutation carriers [10, 12, 13], while two other studies did not
detect a difference between BRCA1 and BRCA2 mutation
carriers and controls [11, 32]. Differences in outcome may
be the result of variances in study design, in particular the
inclusion of breast cancer patients [10] and women with ir-
regular menstrual cycles and/or polycystic ovarian syndrome
[11–13], the lack of appropriate adjustment for potential con-
founding factors in the analysis [10, 11], and/or power issues
[32]. Pregnancy rate and parity in BRCA1/2 mutation carriers
were not different from controls [14–16]. Some studies even
report more pregnancies and children born per mother among
BRCA1/2 mutation carriers [17, 18].
Our study provides additional evidence for a reduced ovarian
reserve in BRCA1mutation carriers, although the effect size was
rather small and the oocyte yield was in the range of a normal
response for all subgroups. Consequently, our finding may be
more interesting from a biological point of view than relevant





p value BRCA1 subgroup
(n = 18)
p valuea BRCA2 subgroup
(n = 20)
p valuea











Cumulus oocyte complexes (median, IQR)b 9.0 (5.8–11.0) 10.0 (7.0–14.0) 0.05 8.5 (5.0–11.3) 0.13 9.0 (6.0–10.8) 0.14
Mature oocytes (median, IQR)b 7.0 (4.0–9.0) 8.0 (6.0–11.0) 0.02 6.5 (4.0–8.0) 0.02 7.5 (5.5–9.0) 0.20
FSH/mature oocyte (median, IQR)b 353.0 (210.7–521.9) 250.0 (168.6–375.0) 0.03 383.0 (208.3–521.9) 0.06 326.3 (203.6–600.0) 0.14
Fraction of normally fertilized oocytes
(2PN) per injected oocyte (median, IQR)b
0.7 (0.7–0.8) 0.7 (0.6–0.9) 0.89 0.8 (0.7–0.8) 0.46 0.7 (0.6–0.8) 0.62
Fraction of embryos biopsied for PGD per
injected oocyte (median, IQR)b
0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.63 0.8 (0.7–0.8) 0.21 0.7 (0.5–0.8) 0.63
Fraction of aneuploid embryos per injected
oocyte (median, IQR)b,c
0.0 (0.0–0.1) 0.1 (0.0–0.2) 0.04 0.1 (0.0–0.2) 0.95 0.0 (0.0–0.0) 0.00
Cycles with embryonic transfer (n, %)d 34/38 (89.5) 129/154 (83.8) 0.38 17/18 (94.4) 0.23 17/20 (85.0) 0.89
Pregnancy with fetal heart beat at 7 weeks
of gestation (n, %)d,e
10/34 (29.4) 39/129 (30.2) 0.93 3/17 (17.6) 0.28 7/17 (41.2) 0.36
IVF in vitro fertilization, PGD preimplantation genetic diagnosis, FSH follicle stimulating hormone, IQR interquartile range, PN pronuclei
a Compared to the control group
bAnalyzed using the Mann-Whitney U test
c Aneuploid for the chromosome analyzed during PGD
dAnalyzed using the chi-square test
e Only cycles included which resulted in embryonic transfer
Table 4 Multivariable analyses
Number of mature oocytes (linear regression analysis)
Β SE p
BRCA1/2 vs. controls −0.28 0.13 0.04
BRCA1 vs. controls −0.45 0.18 0.02
BRCA2 vs. controls −0.12 0.17 0.50
Adjusted for treatment center, female age, female body mass index, type of gonadotropin used, and total dosage of
gonadotropins administered
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for clinical practice. The strengths of our study are (a) the large
homogeneous cohort of BRCA1/2 mutation carriers without re-
cent malignant disease [27, 28], (b) the use of the same IVF
protocol including only first cycles, and (c) the application of
frequency matching, resulting in a representative control group.
Our study also has limitations, mainly associated with the retro-
spective study design although the most important outcome data
were complete for all inclusions (supplemental Table 2). Firstly,
during the study period, different IVF protocols were used in the
participating centers. In order to obtain a homogenous stimulat-
ed cohort, we only included couples treated in a long GnRH
agonist-suppressive protocol with at least 150 IU gonadotropins
per day. This selection led to a smaller cohort than initially
powered. Nevertheless, the effect size in the BRCA1 subgroup
was large enough to be detectable. Additionally, this strategy
may have introduced bias due to the exclusion of expected
hyperresponders (treated with lower doses of FSH per day)
and the inclusion of an excess of suspected poor responders,
since in center 5, this IVF protocol was only the first choice in
this subgroup of patients. However, this may have had an effect
on both the BRCA and control groups and a sensitivity analysis
excluding center 5 did not change the primary outcome.
Secondly, since the poor response rate was (non-significantly)
higher in the control group, this could have biased our primary
outcome. Thirdly, we did not have the opportunity to correct for
lifestyle factors (e.g., smoking). Finally, the BRCA1 and
BRCA2 subgroups were still relatively small. Consequentially,
the absence of an effect of BRCA2 dysfunction on ovarian re-
sponse may have been the result of insufficient power.
Despite these limitations, our finding of an impaired re-
sponse to ovarian stimulation in BRCA1 mutation carriers
and not in BRCA2mutation carriers is interesting and confirms
several previous studies. The absence of a(n) (detectable) effect
of BRCA2 dysfunction on ovarian reserve in most studies may
be the result of a true lack of a difference, of insufficient power,
and/or of either a later-in-life-occurring or more subtle decline
in ovarian reserve, corresponding to the lower risk and higher
age at diagnosis of breast and ovarian cancer associated with
BRCA2 mutations [33]. Both BRCA genes are involved in
DNA double-strand break repair, but their biological functions
differ. The association between BRCA1 and BRCA2 and
(reproductive) aging is demonstrated by the involvement of
the BRCA genes in telomere maintenance: telomeres shorten
with age [34, 35]. In human oocytes, DNA double-strand
breaks are more prevalent with increasing age, while BRCA1
expression is reduced by then [10]. BRCA1 plays an important
role in meiotic spindle formation in mice, and BRCA1 mutant
mice had fewer primordial follicles, produced fewer oocytes in
response to ovarian stimulation, had a smaller litter size, and
showed more DNA double-strand breaks in their oocytes with
increasing age than wild-type mice [10, 36]. BRCA2 dysfunc-
tion inmice has been associatedwith insufficient spermatogen-
esis, a depletion of germ cells in female mice, and a higher
frequency of nuclear aberrations in mutant oocytes [37].
However, the involvement of BRCA2 in DNA double-strand
break repair is probably less comprehensive than BRCA1 in-
volvement [38]. Consequentially, it can be hypothesized that
the effect of BRCA2 dysfunction on ovarian reserve is less
powerful than the effect of a BRCA1 mutation and potentially
only becomes visible at increasing age.
If BRCA1/2 mutation carriers are affected with a reduced
ovarian reserve, this might have several clinical consequences,
such as a higher need for fertility treatment, a worse treatment
outcome, an urge for more treatment attempts, and/or higher
doses of fertility drugs. However, the size of the effect found
in our study is probably too small to be of clinical relevance.
Future clinical and molecular studies are needed to provide
more insight into the role of the BRCA(1) gene(s) in the main-
tenance of the ovarian pool.
Conclusions
A reduced yield of mature oocytes was found in BRCA1 mu-
tation carriers undergoing IVF/PGD, suggesting a role of the
BRCA1 gene in the maintenance of ovarian reserve.
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